ClinicalTrials.gg
CompletedNCT00698451Updated Sep 6, 2013Results posted

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

A Phase 2 interventional study of doxorubicin HCL liposome; bevacizumab; carboplatin in Ovarian Neoplasms, Fallopian Tube Neoplasms and Peritoneal Neoplasms, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-06.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Enrollment
19th of 42
54 · median 53
Started
2008
with 2 others
Phase 2
14 of 42
none open now
Registered
9th of 42
by date
Lead sponsor
2 of 42
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 19th largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 2, and was the 9th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

The purpose of this study is to evaluate the response rate (Complete Response (CR) and Partial Response (PR)) to carboplatin and DOXIL treatment in combination with bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancers. All patients will received DOXIL, carboplatin and bevacizumab for a maximum of ten 28-day cycles. Patients will be followed for six months following treatment to assess progression-free survival.

Read the detailed description

DOXIL pegylated liposomal doxorubicin (PLD) is approved for use in patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. Data suggest that combination therapy of carboplatin plus DOXIL provides superior benefit to single agent therapy. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is approved for use in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer and in combination with carboplatin and paclitaxel (treatment of non-small cell lung cancer); and with paclitaxel (first line treatment of metastatic HER2-negative breast cancer). There are data showing bevacizumab has activity in the treatment of ovarian cancer, and it is currently being studied in platinum-sensitive relapsed ovarian cancer in combination with carboplatin/gemcitabine. No data exist on the efficacy and safety of bevacizumab administered with carboplatin and DOXIL. Based on the growing interest of incorporating bevacizumab in to ovarian cancer treatment and the activity seen to date, the evaluation of the combination of carboplatin and DOXIL with bevacizumab is warranted. This is a single arm (one dosing regimen), multicenter, open label (both the patient and the physician know what drug is being given) study in patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers. This study will be conducted in multiple sites across the United States. All patients will receive DOXIL, carboplatin and bevacizumab by intravenous (IV) infusion for a maximum of ten (10) 28-day cycles. A disease response assessment will occur after the completion of Cycles 2, 4, 6, 8 and at the end of treatment. Patients will be followed for six (6) months post-treatment for progression-free survival. Disease progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST). RECIST is an accepted classification for response to treatment with classifications of Complete Response (CR), Partial Response( (PR), Progressive Disease (PD) or Stable Disease (SD).The primary objective of this study is to evaluate the objective response rate (Complete Response (CR) and Partial Response (PR)) to carboplatin and DOXIL treatment in combination with bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancers. The secondary objectives are to assess the safety profile of carboplatin and DOXIL in combination with bevacizumab as well as the following efficacy endpoints: Duration of response, Progression-free Survival, and Time to Progression. Safety will be evaluated using adverse events, clinical laboratory tests, and tests for cardiac function after the first 20 patients have been entered and received at least 2 cycles of therapy. Overall safety will be summarized at study completion. DOXIL (30 mg/m2), and carboplatin (area under the curve (AUC 5)) will be given on Day 1 of each 28-day cycle. Bevacizumab (10 mg/kg) will be given on days 1 and 15 of every 28-day cycle. All treatment will be given by intravenous (IV) infusion and repeated every 4 weeks for up to 10 cycles.

03

Conditions studied

  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms

Keywords

  • Ovarian cancer
  • fallopian tube cancer
  • primary peritoneal cancer
  • DOXIL
  • carboplatin
  • bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer
  • Relapse-free interval of >6 months afer completion of platinum-based chemotherapy
  • (at least one lesion that can be accurately measured in a least 1 dimension)
  • Adequate bone marrow function, renal, and liver function. Normal cardiac function
  • (ECOG) Performance Status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • No patients who have received more than 1 previous regimen of chemotherapy (maintenance is not considered a second regimen)
  • No patients receiving immunotherapy or radiotherapy or patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis
  • No patients who require parenteral hydration or nutrition or have clinical signs or symptoms of gastrointestinal bowel obstruction or perforation
  • No patients with previous or current other than basal cell or squamous cell carcinoma of the skin
  • No patients with cardiovascular disease
  • No patients with a history of bevacizumab or other VEGF or VEGF receptor-targeted agent use.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    001

    doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle

    Drug: doxorubicin HCL liposome; bevacizumab; carboplatin

Interventions

  • Drugdoxorubicin HCL liposome; bevacizumab; carboplatin

    Drug pages: Liposomal doxorubicin · Bevacizumab · Carboplatin

    30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy End Point is the Number of Patients With an Objective Response.

    Objective Response Rate to Treatment is defined as the Proportion of Patients With a Complete Response (CR) or Partial Response (PR). A Complete Response (CR) is the disappearance of all target lesions and a Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD

    Time frame: Approximately 280 days (from start of treatment to the end of 10 cycles of treatment where each cycle is 28 days)

Secondary outcomes

  1. The Secondary Efficacy Endpoints is Duration of Objective Response.

    Objective Response Rate to Treatment Defined as the Proportion of Patients With a Complete Response (CR) or Partial Response (PR) Where a Complete response (CR) is the disappearance of all target lesions and a Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Duration of response: Duration of response was defined only for subjects with CR or PR as the best overall response. It was calculated from the date of first documentation of response to the date of disease progression or death due to progressive disease.

    Time frame: Duration of response was defined only for subjects with CR or PR as the best overall response. It was calculated from the date of first documentation of response to the date of disease progression or death due to progressive disease.

07

Results

Posted Jul 12, 2013

Participant flow

Participant flow — Overall Study
MilestoneDOXIL/CARBOPLATIN/BEVACIZUMAB
Started54
Completed15
Not completed39
Withdrew: Adverse event22
Withdrew: Physician decision2
Withdrew: Protocol violation6
Withdrew: Withdrawal by subject6
Withdrew: Disease progression3

Outcome measures

PrimaryThe Primary Efficacy End Point is the Number of Patients With an Objective Response.

Objective Response Rate to Treatment is defined as the Proportion of Patients With a Complete Response (CR) or Partial Response (PR). A Complete Response (CR) is the disappearance of all target lesions and a Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD

Time frame:
Approximately 280 days (from start of treatment to the end of 10 cycles of treatment where each cycle is 28 days)
Reported as:
Number · Participants
The Primary Efficacy End Point is the Number of Patients With an Objective Response.
ParticipantsDOXIL/CARBOPLATIN/BEVACIZUMAB
The Primary Efficacy End Point is the Number of Patients With an Objective Response.39
Statistical analysis
  • DOXIL/CARBOPLATIN/BEVACIZUMAB · Exact Binomial Distribution · p = 0.05 · Percentage: 72.2 · 95% CI 58.4 to 83.5
SecondaryThe Secondary Efficacy Endpoints is Duration of Objective Response.

Objective Response Rate to Treatment Defined as the Proportion of Patients With a Complete Response (CR) or Partial Response (PR) Where a Complete response (CR) is the disappearance of all target lesions and a Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Duration of response: Duration of response was defined only for subjects with CR or PR as the best overall response. It was calculated from the date of first documentation of response to the date of disease progression or death due to progressive disease.

Time frame:
Duration of response was defined only for subjects with CR or PR as the best overall response. It was calculated from the date of first documentation of response to the date of disease progression or death due to progressive disease.
Reported as:
Median · Days
The Secondary Efficacy Endpoints is Duration of Objective Response.
DaysDOXIL/CARBOPLATIN/BEVACIZUMAB
The Secondary Efficacy Endpoints is Duration of Objective Response.362 (282 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOXIL/CARBOPLATIN/BEVACIZUMAB—15/54 (27.8%)53/54 (98.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventDOXIL/CARBOPLATIN/BEVACIZUMAB
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders2/54
Deep Vein ThrombosisVascular disorders2/54
ConstipationGastrointestinal disorders1/54
Large Intestinal ObstructionGastrointestinal disorders1/54
NauseaGastrointestinal disorders1/54
Small Intestinal ObstructionGastrointestinal disorders1/54
Small Intestinal PerforationGastrointestinal disorders1/54
Abdominal AbscessInfections and infestations1/54
BacteraemiaInfections and infestations1/54
Staphylococcal InfectionInfections and infestations1/54
Most frequent other events
Showing 10 of 79
Most frequent other events
EventDOXIL/CARBOPLATIN/BEVACIZUMAB
FatigueGeneral disorders32/54
NauseaGastrointestinal disorders31/54
AnaemiaBlood and lymphatic system disorders28/54
ThrombocytopeniaBlood and lymphatic system disorders28/54
EpistaxisRespiratory, thoracic and mediastinal disorders28/54
NeutropeniaBlood and lymphatic system disorders23/54
HeadacheNervous system disorders23/54
StomatitisGastrointestinal disorders20/54
LeukopeniaBlood and lymphatic system disorders20/54
HypertensionVascular disorders20/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DOXIL/CARBOPLATIN/BEVACIZUMAB
<=18 years0
Between 18 and 65 years32
>=65 years22
Age Continuous
Age Continuous(years)DOXIL/CARBOPLATIN/BEVACIZUMAB
Mean62.1 ± 9.00
Sex: Female, Male
Sex: Female, Male(Participants)DOXIL/CARBOPLATIN/BEVACIZUMAB
Female54
Male0
Region of Enrollment
Region of Enrollment(participants)DOXIL/CARBOPLATIN/BEVACIZUMAB
United States54
08

Study locations

1 site
  • Horsham, Pennsylvania 19044, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 17, 2008
Start
Aug 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Jul 12, 2013
Last update
Sep 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00698451
Responsible party
Sponsor
First posted
Jun 17, 2008
Start date
Aug 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Jul 12, 2013
Last update
Sep 6, 2013

Study contacts

Tracey McGowan, MD
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Bevacizumab · Carboplatin

Start the discussion